Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.
Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.
复制标题
DOI：
10.1016/j.bbmt.2011.11.030
复制
发表时间：
2012-03
影响因子：
4.3
通讯作者：
Miller, Jeffrey S.
中科院分区：
文献类型：
--
作者：
Warlick, Erica D.;Defor, Todd;Blazar, Bruce R.;Burns, Linda;Vemeris, Michael R.;Ustun, Celalettin;Weisdorf, Daniel J.;Miller, Jeffrey S.
Few therapeutic strategies exist for hematologic malignancies relapsing postallogeneic hematopoietic cell transplant. We present outcomes on 35 patients with nonchronic myelogenous leukemia (CML) hematologic malignancies, the majority having acute myelogenous leukemia (AML) or myelodysplastic syndromes/myeloproliferative disorders (MDS/MPD) (n = 22) receiving lymphodepleting chemotherapy followed by donor lymphocyte infusion (DLI) at 2 T cell dose levels (0.5 and 1.0 × 108 CD3/kg). Forty-nine percent of patients achieved complete remission (CR), with a median duration of remission of 6 months (range: 2-71+). CR rates were similar between the 2 groups. The incidence of acute graft-versus-host disease (aGVHD) of any grade was 49%. We saw a higher incidence of grade II-IV aGVHD with a rate of 66% using the higher dose DLI (grade III, 33% and grade 4, 20%) versus only 25% (10% grade III-IV) with the lower dose DLI (P = .06). Overall survival at 1 and 2 years was 30% (95% confidence interval [CI], 16%-45%) and 19% (95% CI, 8%-34%); however, for those achieving CR, 1- and 2-year survival was improved at 44% (95% CI 20%-66%) and 28% (95% CI, 8%-52%) (P = .03), respectively. These results demonstrate that DLI after lymphodepleting chemotherapy for relapsed hematologic malignancies results in frequent CRs. The lower DLI dose regimen improved the tolerability of this therapeutic approach, with modest rates of severe aGVHD.
登录
查看更多内容
DOI：
10.1097/cji.0b013e3181b88ffc
发表时间：
2010-01
期刊：
Journal of immunotherapy (Hagerstown, Md. : 1997)
影响因子：
--
作者：
Wrzesinski C;Paulos CM;Kaiser A;Muranski P;Palmer DC;Gattinoni L;Yu Z;Rosenberg SA;Restifo NP
通讯作者：
Restifo NP
影响因子：
11.8
作者：
Deol A;Lum LG
通讯作者：
Lum LG
影响因子：
45.3
作者：
Schmid, Christoph;Labopin, Myriam;Rocha, Vanderson
通讯作者：
Rocha, Vanderson
影响因子：
45.3
作者：
Dudley, ME;Wunderlich, JR;Rosenberg, SA
通讯作者：
Rosenberg, SA
影响因子：
50.5
作者：
Bishop, M. R.;Dean, R. M.;Fowler, D. H.
通讯作者：
Fowler, D. H.